VTUS: Glass half full, ... I too was surprised by the continued upward buying after selling at $3.20 earlier, but 20% is still 20% ... there are other stocks in the sea ...

PBMD... Calm before the storm? Adding this one to my portfolio with catalyst 2.5 weeks away per Sheff's Rec

NBY back to entry pricing for Sheff portfolio and appears to be on the bottom of the flag pattern. ... bought shares at ~$1.38

FLML back up 7% after dropping 7% late yesterday. This seems poised to move higher into coming catalyst

PRAN at 2.85, popping up again today 17% ... sold half position at $2.65 and holding rest, either insiders know good message on 3/4 presentation coming or lots of hopeful thinking, ... any insight/opinions from the collective minds here appreciated.

PRAN is breaking out with volume from $2.19 entry on 2/19 ... up 12% on the day.

Thanks, kook. I was aware of the Phase IIB and the 32-week trial. But I didnt know about the mid-term eval. good to know. been tracking this one for awhile ... You got a follow from me!

PRAN appears to breaking out, technically speaking... Does anyone know of upcoming events for this one? Thanks in advance.

Question: Where does the FDA release a "preliminary review" ahead of adcom? I could not find it on the website. Strange that this one article is all that referenced this review.

So we get 47% of new company (~half) but add a revenue stream of 16M over 1M now ... wish we knew what earnings were at ANI ... then we could apply industry average PPE and get a handle on where the price should be

Agreed. double is a conservative guess lacking hard number estimates. just trying to illustrate long term logic.

This pending approval has been known for awhile ...
serious investors have 6 months to slowly accumulate before seeing real market appreciation.
If you were coming in, would you buy after seeing all the " i'm selling" posts?
there is no incentive to buy high today.
BUT given this stock didnt double/triple in a runup and is fairly close to its average pps, this IS a good time to buy at these prices if looking to buy it and forget it.
Basically, no catalyst to move share price until money rolls in, agreements in place, buy out, etc.
All IMO

I realize most posters and readers are day or swing traders, but consider this for a long term approach: production by Q2 2011 means this gem should realistically double by then on anticipated sales. a resulting market cap of $44M for a known, widely-used, higher dosage product?

Please... show me your 401K or mutual fund double in 1/2 year. This is a incredibly understated simple decision long term bet. if cautious, buy 1/2 of planned investment amount now, buy 1/4 more at next resistance (down, if any), 1/4 more at next resistance (down/up) and sit until July.

All IMO. it beats this...
http://ih.fotothing.com/50108.jpg

The IGXT website shows approval

http://www.intelgenx.com/technologies/tech-prod.html

Just coming back to this stock ... has it been suspended again?

This is buy time. hitting support levels at highest low. Should go to at least .057 at minimum (20%+ from current) to hit lowest high trendline but i expect to go higher since the 6/2 spike broke up through the previous trend resistance.

I have been a shareholder for 2 years with justified hopes for this company. The recent 20% increase is within the trading range for the past 8 months with "legitimate" news to justify the move (unless the new release was false).

I dont see how "pumpers" can be faulted for the current movement directly, although maybe someone can answer this one ...

How can the Mike (owner/CEO) post on this board and that not be considered providing information on his own speculation for a few versus formal news releases via marketwire etc.? Maybe that is what is also being addressed in this.

Given the familiarity with the other stocks in this group it seems odd that this company would be included. However, the SEC is not necessarily stupid on these matters and I suspect has a compelling reason for halting this stock versus going after specific posters or forums.

It is sad. I hope for the tried and true longs (like me) in this that the issue is benign. we certainly appeared to be on an uptrend with recent activity.

Onerung

PRAN ($4.20) ... Thanks. wish I would've noticed this earlier yesterday to alert more on this board given the help received here. I appreciate you and your mods greatly.

PRAN ($3.80) - Jumped in at 3.57 this AM. kicking myself for not spotting strong momentum trend yesterday morning and not reading news until yesterday after market close.

Phase II only at present
http://www.pranabio.com/img/pipeline_0601.gif
with market cap at $90MM ... $95MM
no reason this should not be $200MM market cap with promising pipeline and dramatic potential in treatment

PRAN (2.70) - RE: Alzheimers, article published shows "treatment ... showed a statistically significant increase in the numbers of spines on the branches (or dendrites) of neurons in the hippocampus, a memory centre specifically affected in AD."

Ramifications on ALS and Huntingtons would also be significant. I have been keenly aware of Biopharma progress in "slowing down deterioration" (ie extending life by months) but not on regrowth of neuron dendrites, potentially reversing the damage of these diseases.

I am not in this as I read into it after closing but would appreciate sage input as to stock worthiness. ( I have a best friend with ALS, which partly fuels my interest).

Thanks,
Onerung

wow. wonders never cease.

I am not in the financials industry, but all the information you needed on this trade was on pg 32 of the previous 10-k and on the FAQ page of the APP website. All you who are blaming others are imbecilicably amazing (had to make up that word for the occasion). why would you beleive posts on a boardsite anyway? its called "due diligence" for a reason. look at my previous posts.

I suggest to you all find those individuals who post good DD with factual or reasonably extrapolated data from official press releases or established analysts and stick with them (i do not mean me necessarily; there are others who have proven track records of integrity such as $heff on premium boards). Vet the posters on past posts before you buy.

I got in at .045 based on technical pattern and exited .103 and .085 after further DD review. it wasnt even worth "hoping" for potential windfall with a CVR lottery ticket once I added up the numbers potential from the 10-q and press releases (see earlier post). If I had been wrong, at least I could justify why I had exited. Not because "someone said to buy it on a website and a really really official sounding analyst said it was going to 6 dollars fo' shizzle". Did anyone look up Crixion? their track record? you would not have found much.

Can't speak to Gekko, but he was following and sharing his logic saying to play $100 bucks or less. dont blame him for catastrophic losses. but I found little in his posts to substantiate the wishing, hence my own DD.

This stock is trading/will trade in a slowly downward pattern until delisting rising on short term oversold conditions or the hopes for a shareholder audit (but $100M is a pretty big gap). Unless you daytrade with steely precision and want to play trends between resistances (i do not), I would suggest you thank you lucky stars it still trades and get out while you still can salvage some value. it is not worth the anxiety. As a former 2 year investor in WAMKQ until last spring, I should know. That expensive lesson helped me get "real" about this investment and get out at the right time. I hope you all negatively affected by this stock learn that too for the next "100% guaranteed, to-the-moon, posted-all-over-the-place, certified, sure-fire, one-in-a-million, years-best-buy, retirement-setting, winner" of a stock.

GLTA

This seems like reckless speculation. purely a momentum play between resistances.

a) This company should have provided some level of vague guidance for range of PPS through/after end of year. The lack thereof (and no response from "real" analysts - not crixion) makes cashing out with this CVR highly improbable.
b) All the promise of APP and growing and booming means nothing to the CVR whose track record ended 12/31.
c) if big money is in the know, then this should be higher. The fact that it isn't speaks volumes.
d) the current price (~.118) assumes a 4Q EBITDA of ~$275MM. ($1MM over $267MM earnings per ~1.5 cents). That amount is ~80% of the prior 9 months EBITDA (339MM). From the 10-Q's, for 2010 1Q, 2Q and 3Q "gross profit" was only $97MM $138 MM and $186MM, respectively. Assuming parabolic trajectory (+$40MM -> +$50MM -> +$60MM?), that puts us at $245MM "gross profit" for Q4. The only press releases for new drugs this Q were "Metoprolol Tartrate Injection (According to IMS Health, similar Lopressor sales in the United States for 2009 were approximately $13 million)" and Topotecan for Injection, (According to IMS data, U.S. sales of similar Hycamtin®, in 2009 were $157.1million) Even assuming immediate sales and 50% market penetration (would be amazing) for 1/4 of the year, that is only adding ~$20MM (.5 X $170MM X 1/4 of year) to $265MM in gross profit if this was not already included in the parabolic earnings increase. Thats GROSS PROFIT not EBITDA.

Odd too, some posters have indicated that Fresenius would "gladly" pay the CVR to $6 to show what a great company they purchased. Ludicrous.
from the 10-Q,

Ya know, a little guidance from the company since 12/31/10 would have been helpful along the way with this stock. Their silence is either really good news or really bad news (I know, I know ... quite sage of me).

you mean "Million" add 3 zeros

then nada, goose egg, $0.

Figure each CVR penny is worth $666K EBITA over that amount

READ:GOOD TO KNOW
Its annoying to see the fluff pumpers promoting ( and agreeing with themselves on multiple boards) as stock with stats tied to parent cos.

1) This is a big gamble, folks.
2) this is a contingent value right (cvr), not a stock.
3) It will stop trading upon earnings release, planned for next wednesday.
4) It is an all or nothing "investment." This is more of a lottery ticket than a pharma co waiting on FDA approval. At least when a drug approval is missed the stock still has some value afterward.
5) APP needs to show earnings of over $267M in 4th quarter 2010. up to $6 per CVR possible. Face odds are not good given earlier quarters and late TEVA timing. Possible, just low probable. look at pg. 32 of 10-Q for more info and chart http://ih.advfn.com/p.php?pid=nmona&article=45027573
6) MM manipulation is highly active. expect a large drop at anytime to free trailing stop orders and scare others. They've been accumulating and waiting for newbies.
7) Keep this in mind: There are several CVR's out there right now. they are relatively new. Only one for a public company has reached its end. It was unsuccessful and the investors lost everything.

BIGGEST POSITIVE: lots of momentum.

This is of course IMHO

FYI, I am long now with free money from trades over the past week. I am flipping in and out as well. I just don't want people to get hurt putting all eggs in one basket with this CVR. it is starting to remind me of WAMUQ all over again from last year.

This will close higher today IMO, but prepare for MM selloff now to yesterday's close (fill gap) and possibly a little lower. trend resistance is now broken. No news at this time expected to lift. PS. hint, if that happens, that will be buy time around .12 into tomorrow/next week.

buy now. current bid at trendline resistance from yesterday. expect to bounce up from here.

Excellent. That is what I needed to see. I missed that earlier.
I got out earlier this morning. back in with more this afternoon.
Risk looks lore realistic now. Thanks.

Just to understand...

They have to have made net ~$1.2B since the merger in 09/08, and through the last 10-K for 09/10 they have a net loss of ~$250M, so essentially they have to have made (they being APP really) ~$1.5B in the last quarter. Really? they just got approval in December and set up manufacturing AFTER 12/31/10. Even a lottery has realistic odds.

Please someone (anyone!) clarify (with real info) if this is incorrect or something was missed.

It's been 2 hours and no post... i am having withdrawals ...

ARDM (0.27) posted news ...

Aradigm Reports Successful Phase 2b Bronchiectasis Study with Inhaled
Liposomal Ciprofloxacin

"there was a significant mean reduction of 4.2 log10 units in the ARD-3150 group, reflecting an almost sixteen-thousand fold decrease in bacterial load, versus a very small mean decrease of 0.1 log10 units in the placebo group (p=0.004)."

http://ih.advfn.com/p.php?pid=nmona&article=44859280&symbol=ARDM

... tiered, but for our purposes, WAMPQ and WAMKQ are equal, or "on parity," and will divide available funds equitably...

That's about what I gathered as well. Thanks for the confirmation. will keep digging... on my end

Since you acknowledged ... my original post. (missed the ibox instructions initially).

"Opinion on ARDM (0.25)? - Technicals and growing volume attractive.

http://www.prlog.org/10983203-aradigm-corporation-ardm-completes-6-month-phase-2b-study-expects-q4-fda-announcement.html

curious if better resources have more info on company."

Self-removed per Ibox

In case you haven't been here for the past two years and don't have a special bookmarks section for all things WAMU (like me), here is good site to compare ROI between WAMPQ and WAMKQ among other stats.

http://www.streetace.com/calculations.php

I have been neglectful in faithfully following this stock family. Can someone succinctly shed light on the impetus for share appreciation?

**** edit: never mind. got it

Tks,
Onerung

Guys, sorry I sold my $5M in POZN shares back there ... I hit the wrong button... I can get those shares back, right!?!?!?

JK holding long.

Radar stock HNAB (.297) at last resistance until 0.42, increasing volume.

$heff,

re-entry time for AEZS(1.27)?

CPRX up on high vol on upcoming friday presentation on Phase II trial results of drug combating cocaine addiction ... in at $1.45 looking for $3 to $4

From EDGAR filing, they got more than expected from their asset sales ...

"To date, auctions for the sale of four businesses have yielded $1,200 more in proceeds than initially agreed in ‘stalking horse’ sale agreements. In addition, through the sales completed or announced to date, we have preserved 13,000 jobs for our employees with the buyers of these businesses. "

... that's $1.2 Billion!!!!